Uncategorized
Dextenza meets secondary endpoint in phase 3 trial
A phase 3 clinical trial of Dextenza for the treatment of post-surgical inflammation and pain has shown successful secondary endpoint results, according to a press release from Ocular Therapeutix. The bioresorbable intracanalicular insert is designed to release dexamethasone to the ocular surface for up to 30 days. For all measured time points, the secondary endpoint of absence of anterior chamber flare was statistically superior to placebo. On the fourth day after implantation, 46% of patients who received Dextenza had no anterior chamber flare, the release said.